Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in via BSG
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
CME/CPD
Latest content
Current issue
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
CME/CPD
Latest content
Current issue
Archive
Authors
About
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in via BSG
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
INFLIXIMAB
Email alerts
INFLIXIMAB
Assays for measurement of TNF antagonists in practice
Niels
Vande Casteele
Frontline Gastroenterology
Oct 2017,
8
(4)
236-242;
DOI:
10.1136/flgastro-2016-100692
Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis
Anthony
O'Connor
,
Peter J
Hamlin
,
Jennifer
Taylor
,
Christian
Selinger
,
Nigel
Scott
,
Alexander C
Ford
Frontline Gastroenterology
Jul 2017,
8
(3)
203-209;
DOI:
10.1136/flgastro-2016-100749
Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide
Philip
Hendy
,
Ailsa
Hart
,
Peter
Irving
Frontline Gastroenterology
Apr 2016,
7
(2)
122-128;
DOI:
10.1136/flgastro-2014-100527
Use of anti-TNF drug levels to optimise patient management
Konstantinos
Papamichael
,
Adam S
Cheifetz
Frontline Gastroenterology
Oct 2016,
7
(4)
289-300;
DOI:
10.1136/flgastro-2016-100685
Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy
James
Turvill
Frontline Gastroenterology
Jul 2014,
5
(3)
167-175;
DOI:
10.1136/flgastro-2014-100441
Reassessment of Crohn's disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal?
R J
Dart
,
N
Griffin
,
K
Taylor
,
J
Duncan
,
M
Sastrillo
,
J
Sanderson
,
P M
Irving
Frontline Gastroenterology
Jul 2014,
5
(3)
176-182;
DOI:
10.1136/flgastro-2013-100392
Infliximab and anti-infliximab antibody levels in Crohn's disease
Philip
Hendy
Frontline Gastroenterology
Oct 2014,
5
(4)
227-228;
DOI:
10.1136/flgastro-2014-100485
Biosimilars: what's around the corner?
Richard K
Russell
,
Peter
Irving
,
Chris
Probert
Frontline Gastroenterology
Oct 2015,
6
(4)
262-263;
DOI:
10.1136/flgastro-2015-100587
IBD: reproductive health, pregnancy and lactation
Philip
Hendy
,
Georgina
Chadwick
,
Ailsa
Hart
Frontline Gastroenterology
Jan 2015,
6
(1)
38-43;
DOI:
10.1136/flgastro-2014-100430
Medications and malignancy in inflammatory bowel disease
Philip
Hendy
Frontline Gastroenterology
Apr 2014,
5
(2)
78;
DOI:
10.1136/flgastro-2014-100440
Pages
« first
‹ previous
1
2
CLINICAL
Evidence based practice
Guidelines
Gastroenterology
Drugs: gastrointestinal system
Endoscopy
GI bleeding
Angiodysplasia
Neoplasms
Ulcer
Varices
Infection
Campylobacter, Salmonella, Shigella, Escherichia coli
Clostridium difficile
Gastroenteritis
Giardiasis
Helicobacter pylori
Parastic worms
Inflammatory bowel disease
Crohn's disease
Ulcerative colitis
Liver disease
Alcoholic liver disease
Cirrhosis
Hepatitis B
Hepatitis C
Hepatitis other
Nonalcoholic steatosis
Neurogastroenterology
Chronic intestinal pseudo-obstruction
Constipation
Diarrhoea
Dyspepsia
Gastric emptying disorders
Irritable bowel syndrome
Oesophageal dysmotility
Oesophagus
Gastro-oesophageal reflux
Pancreas and biliary tract
Pancreatitis
Small intestine
Coeliac disease
Gastrointestinal hormones
Malabsorption
Stomach and duodenum
Infectious diseases
Oncology
Colon cancer
Gastric cancer
Hepatic cancer
Intestinal cancer
Oesophageal cancer
Pancreatic cancer
Special collections
Editor's choice
(31)
Guidelines, Recommendations and Consensus Statements
GUT Snapshot
Open access
(89)
Press releases
Therapeutic Monitoring
(4)